Literature DB >> 28549086

To Test or Not to Test? Ending the Age-Old Debate for Drug-Resistant Tuberculosis.

Jennifer Furin1, Helen Cox2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28549086      PMCID： PMC5850638          DOI： 10.1093/cid/cix491

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  9 in total

Review 1.  Rational 'DOTS plus' for the control of MDR-TB.

Authors:  M A Espinal; C Dye; M Raviglione; A Kochi
Journal:  Int J Tuberc Lung Dis       Date:  1999-07       Impact factor: 2.373

2.  Systematic drug susceptibility testing: a necessary component of the 'DOTS plus' strategy?

Authors:  P J Grosset
Journal:  Int J Tuberc Lung Dis       Date:  1999-07       Impact factor: 2.373

3.  Optimising molecular diagnostic capacity for effective control of tuberculosis in high-burden settings.

Authors:  W Sabiiti; B Mtafya; D Kuchaka; K Azam; S Viegas; A Mdolo; E C W Farmer; M Khonga; D Evangelopoulos; I Honeyborne; A Rachow; N Heinrich; N E Ntinginya; N Bhatt; G R Davies; I V Jani; T D McHugh; G Kibiki; M Hoelscher; S H Gillespie
Journal:  Int J Tuberc Lung Dis       Date:  2016-08       Impact factor: 2.373

4.  The dilemma of MDR-TB in the global era.

Authors:  P Farmer; J Bayona; M Becerra; J Furin; C Henry; H Hiatt; J Y Kim; C Mitnick; E Nardell; S Shin
Journal:  Int J Tuberc Lung Dis       Date:  1998-11       Impact factor: 2.373

5.  Applicability of the shorter 'Bangladesh regimen' in high multidrug-resistant tuberculosis settings.

Authors:  Giovanni Sotgiu; Simon Tiberi; Rosella Centis; Lia D'Ambrosio; Zhenia Fuentes; Alimuddin Zumla; Giovanni Battista Migliori
Journal:  Int J Infect Dis       Date:  2016-11-02       Impact factor: 3.623

6.  Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis.

Authors:  J Peter Cegielski; Tracy Dalton; Martin Yagui; Wanpen Wattanaamornkiet; Grigory V Volchenkov; Laura E Via; Martie Van Der Walt; Thelma Tupasi; Sarah E Smith; Ronel Odendaal; Vaira Leimane; Charlotte Kvasnovsky; Tatiana Kuznetsova; Ekaterina Kurbatova; Tiina Kummik; Liga Kuksa; Kai Kliiman; Elena V Kiryanova; HeeJin Kim; Chang-ki Kim; Boris Y Kazennyy; Ruwen Jou; Wei-Lun Huang; Julia Ershova; Vladislav V Erokhin; Lois Diem; Carmen Contreras; Sang Nae Cho; Larisa N Chernousova; Michael P Chen; Janice Campos Caoili; Jaime Bayona; Somsak Akksilp
Journal:  Clin Infect Dis       Date:  2014-07-23       Impact factor: 9.079

Review 7.  Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis.

Authors:  Evan W Orenstein; Sanjay Basu; N Sarita Shah; Jason R Andrews; Gerald H Friedland; Anthony P Moll; Neel R Gandhi; Alison P Galvani
Journal:  Lancet Infect Dis       Date:  2009-03       Impact factor: 25.071

8.  WHO's new end TB strategy.

Authors:  Mukund Uplekar; Diana Weil; Knut Lonnroth; Ernesto Jaramillo; Christian Lienhardt; Hannah Monica Dias; Dennis Falzon; Katherine Floyd; Giuliano Gargioni; Haileyesus Getahun; Christopher Gilpin; Philippe Glaziou; Malgorzata Grzemska; Fuad Mirzayev; Hiroki Nakatani; Mario Raviglione
Journal:  Lancet       Date:  2015-03-24       Impact factor: 79.321

Review 9.  Tuberculosis: opportunities and challenges for the 90-90-90 targets in HIV-infected children.

Authors:  Helena Rabie; Lisa Frigati; Anneke C Hesseling; Anthony J Garcia-Prats
Journal:  J Int AIDS Soc       Date:  2015-12-02       Impact factor: 5.396
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.